Daniela Matei
Affiliations: | Biochemistry and Molecular Biology | Indiana University, Bloomington, Bloomington, IN, United States |
Area:
Molecular Biology, OncologyGoogle:
"Daniela Matei"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Wang Y, Situ X, Cardenas H, et al. (2024) Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Wang Y, Duval AJ, Adli M, et al. (2024) Biology-driven therapy advances in high-grade serous ovarian cancer. The Journal of Clinical Investigation. 134 |
Valdivia A, Vagadia PP, Guo G, et al. (2023) Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2). Journal of Medicinal Chemistry. 66: 9445-9465 |
Zhang Y, Wang Y, Zhao G, et al. (2023) Metabolic dependencies and targets in ovarian cancer. Pharmacology & Therapeutics. 245: 108413 |
Barber EL, Chen S, Pineda MJ, et al. (2022) Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer Research Communications. 2: 1293-1303 |
Zhang Y, Wang Y, Valdivia A, et al. (2022) DOT1L Regulates Ovarian Cancer Stem Cells by Activating β-catenin Signaling. Molecular Cancer Research : McR |
Armstrong DK, Alvarez RD, Backes FJ, et al. (2022) NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 972-980 |
Condello S, Prasad M, Atwani R, et al. (2022) Tissue transglutaminase activates integrin-linked kinase and β-catenin in ovarian cancer. The Journal of Biological Chemistry. 102242 |
Chen S, Xie P, Cowan M, et al. (2022) Epigenetic priming enhances anti-tumor immunity in platinum resistant ovarian cancer. The Journal of Clinical Investigation |
Lheureux S, Matei DE, Konstantinopoulos PA, et al. (2022) Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. Journal For Immunotherapy of Cancer. 10 |